The results in this study are in agreement with a study in which extreme albumin levels were identified as a potential clinically meaningful predictor of vedolizumab CL in patients with ulcerative colitis and Crohn's disease (effect size > 25%) [19]. In addition, IgG has been shown to affect CL of daratumumab in patients with multiple myeloma, with approximately 110% higher CL in IgG myeloma patients than in non-IgG myeloma patients [20]. This evidence concerns the gene ALB and ulcerative colitis.